和血明目片联合康柏西普治疗糖尿病性黄斑水肿的临床效果观察

打开文本图片集

[Abstract]Objective：To investigatethe clinical effect and safety Hexue Mingmu Tablets combined with Conbercept in the treatment diabetic macularedema （DME）.Method： A retrospective analysis was conducted on the clinical data 1O4 patients with DME who received treatment inPeople's Hospital Ruijin City from March 2022 to September 2O23，based on diferent treatment regimens，patients were divided into the observation group （52 patients，104 eyes）and the control group （52 patients，104 eyes）.Patients in both groups were treated with intravitreal injection Conbercept，and patients inthe observation group were treated withoral Hexue Mingmu Tablets on this basis.Before treatment and 1 month，3 months，6months and 12 months after treatment，the best corrected visual acuity （BCVA），central foveal thickness （CMT）and adverse reactions were evaluated in two groups. Result：At1 month，3 months，6months，and12 months after treatment，the BCVAand CMT the observation group were lower than those the control group， with statistically significant differences （ P <0.05）; there was no statistically significant difference in the incidence adverse reactions between two groups （ P. >0.05）.Conclusion： The combination Hexue Mingmu Tabletsand Conbercepthasasignificant efectinthetreatment DME，can improve the visual acuity patients，and has high safety.

[KeyWords] Hexue Mingmu TabletsConbercept Diabetic macular edemaBest corrected visual acuity 'entralmacularthickness

First-author'saddress： Otolaryngology Department，People's Hospital Ruijin City，Ruijin342500，

doi：10.3969/j.issn.1674-4985.2025.23.024

糖尿病性黄斑水肿（DME）是糖尿病眼部并发症中最常见的视力损害原因之一，其发病机制复杂，主要与视网膜微血管损伤和血-视网膜屏障破坏有关[1-2]。（剩余4866字）